Research Analysts Set Expectations for PAVmed Q2 Earnings

PAVmed Inc. (NASDAQ:PAVM) – Research analysts at Ascendiant Capital Markets upped their Q2 2026 earnings per share (EPS) estimates for shares of PAVmed in a report released on Friday, June 5th. Ascendiant Capital Markets analyst E. Woo now expects that the company will post earnings of ($0.66) per share for the quarter, up from their previous estimate of ($0.80). Ascendiant Capital Markets has a “Buy” rating and a $56.00 price objective on the stock. The consensus estimate for PAVmed’s current full-year earnings is ($2.74) per share. Ascendiant Capital Markets also issued estimates for PAVmed’s Q3 2026 earnings at ($0.66) EPS, Q4 2026 earnings at ($0.64) EPS, FY2026 earnings at ($2.74) EPS, Q1 2027 earnings at ($0.65) EPS, Q2 2027 earnings at ($0.65) EPS, Q3 2027 earnings at ($0.65) EPS, Q4 2027 earnings at ($0.64) EPS and FY2027 earnings at ($2.55) EPS.

Several other equities research analysts have also commented on the stock. Wall Street Zen upgraded shares of PAVmed from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. Weiss Ratings reiterated a “sell (d)” rating on shares of PAVmed in a report on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, PAVmed currently has an average rating of “Hold” and a consensus target price of $56.00.

PAVmed Stock Performance

Shares of PAVM stock opened at $5.00 on Monday. The business’s fifty day moving average price is $7.47 and its 200 day moving average price is $8.77. The firm has a market capitalization of $5 million, a PE ratio of -0.13 and a beta of 0.58. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.02 and a quick ratio of 2.02. PAVmed has a 1-year low of $4.50 and a 1-year high of $28.44.

PAVmed (NASDAQ:PAVM) last posted its quarterly earnings results on Friday, May 15th. The company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.48). PAVmed had a negative net margin of 21,914.12% and a negative return on equity of 146.19%. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.07 million.

Institutional Investors Weigh In On PAVmed

A hedge fund recently raised its stake in PAVmed stock. Geode Capital Management LLC boosted its position in PAVmed Inc. (NASDAQ:PAVM) by 74.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 168,832 shares of the company’s stock after purchasing an additional 72,258 shares during the period. Geode Capital Management LLC owned about 17.23% of PAVmed worth $40,000 as of its most recent SEC filing. 19.93% of the stock is currently owned by institutional investors and hedge funds.

About PAVmed

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.